How to treat primary cutaneous B cell lymphoma – Results from a monocentric cohort study on 98 patients
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15702 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Rohat Cankaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Skin Neoplasms, Lymphoma, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Primary cutaneous B cell lymphomas (CBCL) are chronic diseases with frequent relapses. Time to next treatment (TTNT) is an endpoint reflecting clinical benefit of treatments including patient perspectives. The objectives were to evaluate clinical characteristics, survival, prognosis and TTNT in CBCL. Patients and methods In this monocentric study, clinical data were extracted between 1998 and 2022. TTNT were calculated. Univariate and multivariate analyses were conducted.
Results
Altogether, 46 patients with follicle center lymphoma (pcFCL), 41 with marginal zone lymphoproliferative disorder (pcMZLPD) and 11 with diffuse large B‐cell lymphoma, leg type (DLBCL‐LT) were identified. 26% of pcFCL patients relapsed frequently. The 5‐year relapse‐free survival was 71%, 87% and 23% in pcFCL, pcMZLPD and DLBCL‐LT, respectively. In pcFCL and pcMZLPD, skin‐directed treatments, such as excision or intralesional triamcinolone, performed best based on TTNT, while chemotherapy achieved a mean TTNT of 38 months in DLBCL‐LT. In multivariate analysis of all patients, leg involvement was significantly associated with a decreased TTNT of the first treatment, while comorbidities were associated with an increased TTNT.
Conclusions
DLBCL‐LT had the worst survival. Skin‐directed treatments tend to achieve higher TTNT in pcFCL and pcMZLPD, while systemic treatments had higher TTNT in DLBCL‐LT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Skin Cancer Centre, Charité - Universitätsmedizin Berlin, Berlin, Germany.
ORCID-Profile: Rose Moritz, Gabor Dobos
Zitieren
APA
Cankaya, R., Kleiner, P. L., Hilke, F. J., Moritz, R., Eigentler, T., Schlaak, M., & Dobos, G. (2025). How to treat primary cutaneous B cell lymphoma – Results from a monocentric cohort study on 98 patients. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15702
Vancouver
Cankaya R, Kleiner PL, Hilke FJ, Moritz R, Eigentler T, Schlaak M, et al. How to treat primary cutaneous B cell lymphoma – Results from a monocentric cohort study on 98 patients. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15702
BibTeX
@article{Cankaya2025,
author = {Cankaya, Rohat and Kleiner, Pit Leonard and Hilke, Franz Joachim and Moritz, Rose and Eigentler, Thomas and Schlaak, Max and Dobos, Gabor},
title = {How to treat primary cutaneous B cell lymphoma – Results from a monocentric cohort study on 98 patients},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15702}
}
EUVIMED